[go: up one dir, main page]

MX2012004409A - Proteina recombinante de humano cc10 para el tratamiento de la influenza. - Google Patents

Proteina recombinante de humano cc10 para el tratamiento de la influenza.

Info

Publication number
MX2012004409A
MX2012004409A MX2012004409A MX2012004409A MX2012004409A MX 2012004409 A MX2012004409 A MX 2012004409A MX 2012004409 A MX2012004409 A MX 2012004409A MX 2012004409 A MX2012004409 A MX 2012004409A MX 2012004409 A MX2012004409 A MX 2012004409A
Authority
MX
Mexico
Prior art keywords
rhcc10
recombinant human
influenza
treatment
methods
Prior art date
Application number
MX2012004409A
Other languages
English (en)
Inventor
Aprile Pilon
Pierre Borgeat Ph D
Louis Flamand Ph D
Original Assignee
Clarassance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clarassance Inc filed Critical Clarassance Inc
Publication of MX2012004409A publication Critical patent/MX2012004409A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un sistema de lodos poliméricos inhibitorio a base de agua y método para el uso del sistema de perforación y estabilización de pozos, se describe para el uso en formaciones sensibles al agua como una alternativa a los lodos derivados de aceites minerales. El sistema comprende una poliacrilamida de bajo peso molecular sustancialmente no iónica, en combinación con una poliacrilamida de alto peso molecular sustancialmente no jónica, preferiblemente un alcohol o amina de cadena larga o inhibidor esquistoso de silicatos y celulosa polianiónica.
MX2012004409A 2009-10-15 2010-10-13 Proteina recombinante de humano cc10 para el tratamiento de la influenza. MX2012004409A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25202809P 2009-10-15 2009-10-15
PCT/US2010/052527 WO2011047065A1 (en) 2009-10-15 2010-10-13 Recombinant human cc10 protein for treatment of influenza

Publications (1)

Publication Number Publication Date
MX2012004409A true MX2012004409A (es) 2012-08-23

Family

ID=43876512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004409A MX2012004409A (es) 2009-10-15 2010-10-13 Proteina recombinante de humano cc10 para el tratamiento de la influenza.

Country Status (18)

Country Link
US (1) US8957018B2 (es)
EP (1) EP2488205B1 (es)
JP (2) JP5944316B2 (es)
KR (1) KR101597391B1 (es)
CN (1) CN102834115B (es)
AU (1) AU2010306840B2 (es)
BR (1) BR112012008463A2 (es)
CA (1) CA2813740C (es)
DK (1) DK2488205T3 (es)
ES (1) ES2606541T3 (es)
HU (1) HUE030838T2 (es)
IL (2) IL219009A0 (es)
MX (1) MX2012004409A (es)
NZ (1) NZ599511A (es)
PL (1) PL2488205T3 (es)
PT (1) PT2488205T (es)
RU (1) RU2554745C2 (es)
WO (1) WO2011047065A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
JP5773437B2 (ja) 2008-05-13 2015-09-02 セラブロン，インコーポレイテッド 鼻性鼻炎の治療に使用するための組換えヒトｃｃ１０およびその組成物
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
WO2011047065A1 (en) 2009-10-15 2011-04-21 Clarassance, Inc. Recombinant human cc10 protein for treatment of influenza
US20140274915A1 (en) 2013-03-15 2014-09-18 Clarassance, Inc. Methods of Use for Recombinant Human Secretoglobins
US12162914B2 (en) 2013-03-15 2024-12-10 Apc Research Assets Llc Modification and compositions of human secretoglobin proteins
US9394349B2 (en) 2013-03-15 2016-07-19 Therabron Therapeutics, Inc. Modification and compositions of human secretoglobin proteins
JP2022509856A (ja) * 2018-11-30 2022-01-24 エーピーシー リサーチ アセッツ，エルエルシー ヘパラン硫酸プロテオグリカンタンパク質との相互作用を介してグリコカリックスを保護するためのセクレトグロビンの組成物及び使用方法
US20230241163A1 (en) * 2020-06-02 2023-08-03 Apc Research Assets Llc Recombinant Human CC10 Protein for Treatment of Influenza, Ebola and Coronavirus

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4691009A (en) 1984-12-26 1987-09-01 Repligen Corporation Hybrid proteins produced by an ultrahigh prokaryotic expression system
EP0243449A1 (en) 1985-10-18 1987-11-04 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US4820514A (en) 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
JP2656944B2 (ja) 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US5266562A (en) 1987-11-19 1993-11-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-inflammatory agents
US5354269A (en) 1991-12-20 1994-10-11 Fibrogenex, Inc. Method for treating cancer resections
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5482930A (en) 1993-06-09 1996-01-09 The Regents Of The University Of California Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
US5470885A (en) 1993-09-29 1995-11-28 The Research Foundation Of The State University Of New York Fluorocarbons as anti-inflammatory agents
FR2724665B1 (fr) 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
US5696092A (en) 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers
US5935860A (en) 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
WO1997001627A1 (en) 1995-06-27 1997-01-16 Igen International, Inc. High-level expression and efficient recovery of ubiquitin fusion proteins from escherichia coli
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
WO1997034997A1 (en) 1996-03-21 1997-09-25 Human Genome Sciences, Inc. Human endometrial specific steroid-binding factor i, ii and iii
AU5253998A (en) 1996-11-13 1998-06-03 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
US20030008816A1 (en) 1997-05-28 2003-01-09 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20060025348A1 (en) 1997-05-28 2006-02-02 Pilon Aprile L Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US7122344B2 (en) 1997-05-28 2006-10-17 Claragen, Inc. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US6255281B1 (en) 1997-05-28 2001-07-03 Claragen, Inc. And U.S. Government Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US20030207795A1 (en) 1997-05-28 2003-11-06 Pilon Aprile L. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US20020160948A1 (en) 1998-07-21 2002-10-31 Aprile Pilon Recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US20050261180A1 (en) 1997-05-28 2005-11-24 Pilon Aprile L Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US20040047857A1 (en) 1997-05-28 2004-03-11 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20020169108A1 (en) 1997-05-28 2002-11-14 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
ID28658A (id) 1998-04-16 2001-06-21 Texas Biotechnology Corp Senyawa yang menghambat pengikatan integrin pada reseptornya
AU5836700A (en) 1999-06-01 2000-12-18 Patrick T. Prendergast Peptides for therapeutic use
WO2001032677A1 (en) 1999-11-04 2001-05-10 Human Genome Sciences, Inc. Uteroglobin-like polynucleotides, polypeptides, and antibodies
WO2001079285A1 (en) 2000-04-14 2001-10-25 Claragen, Inc. Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production
US20020025510A1 (en) 2000-07-26 2002-02-28 Strongin Alex Y. Screening methods based on superactivated alpha V beta 3 integrin
WO2003057257A1 (en) * 2002-01-02 2003-07-17 The Johns Hopkins University Cc10 inhibits th2 cytokines and eotaxins involved in allergic diseases
US20090227025A1 (en) * 2003-06-06 2009-09-10 The Board Of Regents Of The University Of Texas System Ex vivo human lung/immune system model using tissue engineering for studying microbial pathogens with lung tropism
EP2262892A4 (en) 2008-04-08 2011-09-21 Amyris Biotechnologies Inc EXPRESSION OF HETEROLOGOUS SEQUENCES
JP5773437B2 (ja) 2008-05-13 2015-09-02 セラブロン，インコーポレイテッド 鼻性鼻炎の治療に使用するための組換えヒトｃｃ１０およびその組成物
WO2011047065A1 (en) 2009-10-15 2011-04-21 Clarassance, Inc. Recombinant human cc10 protein for treatment of influenza

Also Published As

Publication number Publication date
DK2488205T3 (en) 2017-01-16
IL219009A0 (en) 2012-06-28
JP5944316B2 (ja) 2016-07-05
AU2010306840B2 (en) 2015-06-25
PT2488205T (pt) 2016-11-10
CN102834115A (zh) 2012-12-19
AU2010306840A1 (en) 2012-05-17
JP2016155799A (ja) 2016-09-01
HUE030838T2 (en) 2017-06-28
KR101597391B1 (ko) 2016-02-24
PL2488205T3 (pl) 2018-01-31
EP2488205A4 (en) 2013-04-03
RU2554745C2 (ru) 2015-06-27
IL243697A0 (en) 2016-04-21
BR112012008463A2 (pt) 2019-09-24
KR20120098699A (ko) 2012-09-05
ES2606541T3 (es) 2017-03-24
CA2813740C (en) 2016-08-02
CA2813740A1 (en) 2011-04-21
WO2011047065A1 (en) 2011-04-21
NZ599511A (en) 2014-06-27
JP2013508283A (ja) 2013-03-07
EP2488205A1 (en) 2012-08-22
RU2012120671A (ru) 2013-11-20
US20120231997A1 (en) 2012-09-13
EP2488205B1 (en) 2016-09-21
US8957018B2 (en) 2015-02-17
CN102834115B (zh) 2015-01-14

Similar Documents

Publication Publication Date Title
MX2012004409A (es) Proteina recombinante de humano cc10 para el tratamiento de la influenza.
MD4430B1 (ro) Compoziţii şi metode de tratament al hepatitei virale C
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
WO2009140269A3 (en) Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
NZ607477A (en) Non-natural amino acid replication-dependent microorganisms and vaccines
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
HK1198869A1 (en) Combination treatments for hepatitis c
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
BRPI0518861A2 (pt) compostos, sais ou hidratos farmaceuticamente aceitos, composição farmacêutica e métodos de modulação de atividades imuno das citocinas e de tratamento da infecção por vìrus da hepatite c em paciente
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
NZ599930A (en) Pharmaceutical compositions for the stimulation of stem cells.
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
PH12013500559A1 (en) Combination therapy for treating hcv infection
WO2010019717A3 (en) Combination therapy of hiv fusion/entry inhibitors targeting gp41
WO2010138419A3 (en) Materials and methods for treating viral infections
MX336278B (es) Composiciones y metodos para la prevencion y el tratamiento de heridas.
WO2009023356A3 (en) Materials and methods for treating influenza infections
DE602007010127D1 (en) Hiv-impfstoff
WO2008030853A3 (en) Combination therapy for human immunodeficiency virus infection
WO2009070564A3 (en) Compositions and methods for prevention of infection in transcutaneous osseointegrated implants
MX2009006311A (es) Terapia de combinacion para tratar infecciones de hepatitis c.
RU2013129824A (ru) Новое лечение инфекции вируса гепатита с

Legal Events

Date Code Title Description
FG Grant or registration